4Seth SD, Beotra A, Seth S. Comparative bioavailability of two brands of ciprofloxacin [ J ]. J Assoc Physicians India ,1995.43(5) :327 -30.
5Shaha A, Liu MC, Vaughan D, et al. Oral bioequivalence of three ciprofloxacin formulations followingsingle-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension [ J ]. J Antimicrol Chemother, 1999,43 ( Suppl. A) : 49 - 54.
6Om Bergan. Pharmacokinetics of ciprofloxacin intravenous and increasing oral doses[J] .Ame J Medi, 1987,82:97.
7Steven L, Barriere. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlozillin[J]. Antimicrobial and Chemotherapy , 1990:823.
8Tom Bergan.Pharmacokinetics of ciprofloxacin intrarenous and increasing oral doses.The american journal of medieine,April 1987,82:97.
9Steven L,Barriere,Alteration in the pharmacokinetic dis position of ciprofloxacin by simultaneous administration of azlozillin.Antimicrobial Chemotherapy May,1990:823.
10Campoli-Richards DM,Mond JP,Price A.Benfield P.Ciprofloxacin a review of its antibacterial activity pharmacokinetic properties and therapeutic use.Drugs.1988,35:373.
